COVID-19 Vaccines Show Promise in Boosting cancer Immunotherapy Effectiveness
A surprising new study reveals that widely available COVID-19 mRNA vaccines may significantly enhance the effectiveness of immunotherapy treatments for cancer, offering a potential breakthrough for patients with even the most challenging tumors.
The COVID-19 mRNA-based vaccines, credited with saving an estimated 2.5 million lives globally during the pandemic, could hold the key to unlocking a more powerful immune response against cancer. Researchers publishing their findings in the journal Nature have uncovered evidence suggesting these vaccines can “spark” the immune system to more effectively fight cancerous cells.
The discovery stemmed from earlier work conducted in 2016. While developing mRNA vaccines for brain tumors, a team led by pediatric oncologist Elias Sayour found that mRNA could be used to train immune systems to target and destroy tumors, even those unrelated to the vaccine’s initial target. This led researchers to hypothesize that the mRNA vaccines designed to combat SARS-CoV-2 might also exhibit antitumor properties.
To investigate this possibility, the team analyzed clinical outcomes for over 1,000 patients with late-stage melanoma and lung cancer undergoing treatment with immune checkpoint inhibitors – a common immunotherapy approach. These inhibitors work by blocking proteins that cancer cells use to suppress the immune system, allowing immune cells to continue attacking the tumor.
The results were remarkable. Patients who received either the Pfizer or Moderna mRNA-based COVID-19 vaccine within 100 days of starting immunotherapy were more than twice as likely to be alive after three years compared to those who did not receive the vaccine. Perhaps even more significantly,patients with tumors that typically respond poorly to immunotherapy showed a especially strong benefit.
Though, significant research is underway to develop personalized mRNA vaccines specifically tailored to individual cancer patients. This involves analyzing a patient’s tumor and using machine learning to identify the most promising protein targets for a vaccine. Though, this personalized approach can be costly and complex to manufacture.
The advantage of utilizing existing COVID-19 mRNA vaccines lies in their widespread availability, low cost, and ease of administration. “Our findings that COVID-19 mRNA vaccines have substantial antitumor effects bring hope that they could help extend the anti-cancer benefits of mRNA vaccines to all,” researchers stated.
Next Steps: A Nationwide Clinical Trial
To further explore this promising avenue, a nationwide clinical trial is being prepared for patients with lung cancer.Participants receiving an immune checkpoint inhibitor will be randomly assigned to either receive a COVID-19 mRNA vaccine during treatment or a placebo.
The results of this trial will determine whether incorporating a COVID-19 mRNA vaccine into the standard of care for patients undergoing immune checkpoint inhibitor therapy is warranted. Ultimately, the goal is to improve outcomes for all cancer patients receiving immunotherapy, particularly those with limited treatment options.
This research exemplifies the potential for tools developed during a global pandemic to be repurposed as powerful new weapons in the fight against cancer, rapidly expanding the benefits of existing treatments to a broader population. By leveraging a familiar vaccine in an innovative way, researchers hope to extend the life-saving benefits of immunotherapy to cancer patients who have been left behind.
More details: Steven Lin, SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade, Nature (2025).DOI: 10.1038/s41586-025-09655-y. www.nature.com/articles/s41586-025-09655-y
Provided by The Conversation.
Citation: COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment (2025, October 25) retrieved 26 October 2025 from https://medicalxpress.com/news/2025-10-covid-mrna-vaccines-revolution-cancer.html.
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part might potentially be reproduced without the written permission. The content is provided for information purposes only.
